Binding of proteins to PEGylated liposomes and improvement of G-CSF efficacy in mobilization of hematopoietic stem cells

Journal of Controlled Release

Volumn 135, Issue 1, 2009, Pages 44-50

  Yatuv, Rivka ^a   Carmel Goren, Lea ^a   Dayan, Inbal ^a   Robinson, Micah ^a   Baru, Moshe ^a  

^a Omri Laboratories Ltd   (Israel)

Author keywords

G CSF; Hematopoietic stem cell mobilization; PEGylated liposomes

Indexed keywords

AMINO ACID SEQUENCES; BONE MARROW TRANSPLANTATIONS; BONE MARROWS; CIRCULATION TIME; COAGULATION FACTORS; CONSENSUS SEQUENCES; G-CSF; GRANULOCYTE COLONY-STIMULATING FACTORS; HEMATOPOIETIC STEM CELL MOBILIZATION; HIGH AFFINITIES; INTRAVENOUS INJECTIONS; PEGYLATED LIPOSOMES; PERIPHERAL BLOODS; PHARMACOKINETIC STUDIES; SURFACE PLASMONS;

AMINES; AMINO ACIDS; BONE; CELLS; COAGULATION; ORGANIC ACIDS; PHOSPHOLIPIDS; PROTEINS; SURFACE PLASMON RESONANCE;

LIPOSOMES;

LIPOSOME; NEUTROMAX; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BLOOD; BONE MARROW; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; HEMATOPOIETIC STEM CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL MOBILIZATION; SURFACE PLASMON RESONANCE;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CONSENSUS SEQUENCE; FLOW CYTOMETRY; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; INJECTIONS, INTRAVENOUS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; POLYETHYLENE GLYCOLS; PROTEIN BINDING;

EID: 61849169007     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.12.004     Document Type: Article

References (41)

1. Klibanov A.L., Maruyama K., Torchilin V.P., and Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268 1 (1990) 235-237
2. Gabizon A.A., Barenholz Y., and Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm. Res. 10 5 (1993) 703-708
3. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., and Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54 4 (1994) 987-992
4. Kaufman R., Antonarakis S., and Fay P. In: Colman R.W., Hirsh J., Marder V.J., Clowes A.W., and George J.N. (Eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice (2001), Lippincott Williams & Wilkins, Philadelphia 135-156
5. Baru M., Carmel-Goren L., Barenholz Y., Dayan I., Ostropolets S., Slepoy I., Gvirtzer N., Fukson V., and Spira J. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb. Haemost. 93 6 (2005) 1061-1068
6. Spira J., Plyushch O.P., Andreeva T.A., and Andreev Y. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with PEGylated liposomes. Blood 108 12 (2006) 3668-3673
7. Powell J.S. Liposomal approach towards the development of a longer-acting factor VIII. Haemophilia 13 Suppl 2 (2007) 23-28
8. Powell J.S., Nugent D.J., Harrison J.A., Soni A., Luk A., Stass H., and Gorina E. Safety and pharmacokinetics of a recombinant factor VIII with PEGylated liposomes in severe hemophilia A. J. Thromb. Haemost. 6 2 (2008) 277-283
9. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin. Thromb. Hemost. 26 4 (2000) 425-432
10. Yatuv R., Dayan I., Carmel-Goren L., Robinson M., Aviv I., Goldenberg-Furmanov M., and Baru M. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia 14 3 (2008) 476-483
11. Roberts A.W. G-CSF: a key regulator of neutrophil production, but that's not all!. Growth Factors 23 1 (2005) 33-41
12. Anderlini P., and Korbling M. The use of mobilized peripheral blood stem cells from normal donors for allografting. Stem Cells 15 1 (1997) 9-17
13. Jansen J., Hanks S., Thompson J.M., Dugan M.J., and Akard L.P. Transplantation of hematopoietic stem cells from the peripheral blood. J. Cell. Mol. Med. 9 1 (2005) 37-50
14. Layton J.E., Hockman H., Sheridan W.P., and Morstyn G. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 74 4 (1989) 1303-1307
15. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., Bennett C.L., Cantor S.B., Crawford J., Cross S.J., Demetri G., Desch C.E., Pizzo P.A., Schiffer C.A., Schwartzberg L., Somerfield M.R., Somlo G., Wade J.C., Wade J.L., Winn R.J., Wozniak A.J., and Wolff A.C. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 24 19 (2006) 3187-3205
16. Anderlini P., Przepiorka D., Seong C., Smith T.L., Huh Y.O., Lauppe J., Champlin R., and Korbling M. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 37 5 (1997) 507-512
17. Holm M. Not all healthy donors mobilize hematopoietic progenitor cells sufficiently after G-CSF administration to allow for subsequent CD34 purification of the leukapheresis product. J. Hematother. 7 2 (1998) 111-113
18. Tricot G., Jagannath S., Vesole D., Nelson J., Tindle S., Miller L., Cheson B., Crowley J., and Barlogie B. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 85 2 (1995) 588-596
19. Stiff P., Gingrich R., Luger S., Wyres M.R., Brown R.A., LeMaistre C.F., Perry J., Schenkein D.P., List A., Mason J.R., Bensinger W., Wheeler C., Freter C., Parker W.R.L., and Emmanouilides C. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant. 26 5 (2000) 471-481
20. Siena S., Schiavo R., Pedrazzoli P., and Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J. Clin. Oncol. 18 6 (2000) 1360-1377
21. Jonsson U., Fagerstam L., Ivarsson B., Johnsson B., Karlsson R., Lundh K., Lofas S., Persson B., Roos H., Ronnberg I., et al. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. BioTechniques 11 5 (1991) 620-627
22. Bachar-Lustig E., Li H.W., Gur H., Krauthgamer R., Marcus H., and Reisner Y. Induction of donor-type chimerism and transplantation tolerance across major histocompatibility barriers in sublethally irradiated mice by Sca-1(+)Lin(-) bone marrow progenitor cells: synergism with non-alloreactive (host x donor)F(1) T cells. Blood 94 9 (1999) 3212-3221
23. de Kruijf E.J., van Pel M., Hagoort H., Kruysdijk D., Molineux G., Willemze R., and Fibbe W.E. Repeated hematopoietic stem and progenitor cell mobilization without depletion of the bone marrow stem and progenitor cell pool in mice after repeated administration of recombinant murine G-CSF. Hum. Immunol. 68 5 (2007) 368-374
24. Neipp M., Zorina T., Domenick M.A., Exner B.G., and Ildstad S.T. Effect of FLT3 ligand and granulocyte colony-stimulating factor on expansion and mobilization of facilitating cells and hematopoietic stem cells in mice: kinetics and repopulating potential. Blood 92 9 (1998) 3177-3188
25. Broxmeyer H.E., Orschell C.M., Clapp D.W., Hangoc G., Cooper S., Plett P.A., Liles W.C., Li X., Graham-Evans B., Campbell T.B., Calandra G., Bridger G., Dale D.C., and Srour E.F. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201 8 (2005) 1307-1318
26. Spira J., Plyushch O.P., Andreeva T.A., and Khametova R.N. Evaluation of liposomal dose in recombinant factor VIII reconstituted with PEGylated liposomes for the treatment of patients with severe haemophilia A. Thromb. Haemost. 100 3 (2008) 429-434
27. Allen T.M., Hansen C.B., and Guo L.S. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim. Biophys. Acta 1150 1 (1993) 9-16
28. ® prescribing information. http://www.neupogen.com/pi.html
29. Toor A.A., Ayers J., Strupeck J., Parthasarathy M., Creech S., Rodriguez T., and Stiff P.J. Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. Br. J. Haematol. 124 6 (2004) 769-776
30. Goldberg S.L., Mangan K.F., Klumpp T.R., Macdonald J.S., Thomas C., Mullaney M.T., and Au F.C. Complications of peripheral blood stem cell harvesting: review of 554 PBSC leukaphereses. J. Hematother. 4 2 (1995) 85-90
31. ® prescribing information. http://www.neulasta.com/professional/pi.jsp
32. Holmes F.A., Jones S.E., O'Shaughnessy J., Vukelja S., George T., Savin M., Richards D., Glaspy J., Meza L., Cohen G., Dhami M., Budman D.R., Hackett J., Brassard M., Yang B.B., and Liang B.C. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann. Oncol. 13 6 (2002) 903-909
33. Green M.D., Koelbl H., Baselga J., Galid A., Guillem V., Gascon P., Siena S., Lalisang R.I., Samonigg H., Clemens M.R., Zani V., Liang B.C., Renwick J., and Piccart M.J. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann. Oncol. 14 1 (2003) 29-35
34. Tanaka H., Satake-Ishikawa R., Ishikawa M., Matsuki S., and Asano K. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. Cancer Res. 51 14 (1991) 3710-3714
35. Kotto-Kome A.C., Fox S.E., Lu W., Yang B.B., Christensen R.D., and Calhoun D.A. Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol. Res. 50 1 (2004) 55-58
36. Steidl U., Fenk R., Bruns I., Neumann F., Kondakci M., Hoyer B., Graf T., Rohr U.P., Bork S., Kronenwett R., Haas R., and Kobbe G. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of PEGylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 35 1 (2005) 33-36
37. Russell N., Mesters R., Schubert J., Boogaerts M., Johnsen H.E., Canizo C.D., Baker N., Barker P., Skacel T., and Schmitz N. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 93 3 (2008) 405-412
38. Flomenberg N., Devine S.M., Dipersio J.F., Liesveld J.L., McCarty J.M., Rowley S.D., Vesole D.H., Badel K., and Calandra G. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 106 5 (2005) 1867-1874
39. Kroger N., Sonnenberg S., Cortes-Dericks L., Freiberger P., Mollnau H., and Zander A.R. Kinetics of G-CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte-stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study. Transfusion 44 1 (2004) 104-110
40. Constantinescu I., Levin E., and Gyongyossy-Issa M. Liposomes and blood cells: a flow cytometric study. Artif Cells Blood Substit. Immobil. Biotechnol. 31 4 (2003) 395-424
41. Levesque J.P., Hendy J., Takamatsu Y., Simmons P.J., and Bendall L.J. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J. Clin. Invest. 111 2 (2003) 187-196